May 13-15, 2025 | Boston, MA www.precision-medicine-in-ibd.com

**LIMITED TICKETS** REMAINING

WELCOME



### **3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit**

Deliver Safe & Effective Precision Therapies to Every IBD Patient

**Enhance Stratification, Response Rate & Efficacy of IBD Therapies** for Unmet Patient Needs with **Advances in Multi-Omics, AI & Clinically Validated Biomarkers** 

### **Expert Speakers Include:**



Judy Chou President & CEO AltruBio



Sarah Grant Vice President & Head, Early Clinical Development, **Respiratory &** Immunology AstraZeneca



Professor of Medicine & Director, University Hospital Schleswig-Holstein (UKSH) at

**Stefan Schreiber** 

SPYRE

Joshua Friedman Senior Vice President, Clinical Development Therapeutics



**Proud to Partner With:** 

alimentiv discovery accelerated.

Raj Kamath Executive Director Merck & Co.

Perspectum (



Department of Internal Medicine **Kiel University** 

Ilan Wapinski Head of **Biomarkers** & Patient Stratification Sanofi



+1 617 455 4188 info@hansonwade.com www.precision-medicine-in-ibd.com

nference<sup>®</sup>

### Welcome to the 3<sup>rd</sup> Precision Medicine in Inflammatory Bowel Disease Summit

Patients with inflammatory bowel disease (IBD) face limited treatment options, which lack efficacy, driven by the heterogeneous nature of the disease. However, transformative advancements in disease understanding, AI-powered biomarker development, patient stratification, and advanced monitoring technologies are paving the way for a new era of precision IBD therapies for patients with unmet needs.

Returning as the definitive meeting for industry and academic leaders, the **3**<sup>rd</sup> **Precision Medicine in Inflammatory Bowel Disease Summit** provides an unparalleled opportunity to explore groundbreaking advancements in IBD drug development, refine precision medicine strategies, and accelerate the development of transformative treatments – ensuring the right drug reaches the right patient, at the right time.

This year's program has been curated with insights from 25+ world-class speakers from the likes of **AstraZeneca**, **Genentech**, **Regeneron** and **Palatin Technologies**, showcasing the latest data and advances in IBD therapeutic development, including:

- **Refining models and proof-of-concept studies** to reduce clinical trial failure rates and improve translational outcomes for better treatments for patients
- Innovating treatment pathways to optimize safety and efficacy in precision medicine for IBD with actionable non-clinical and clinical insights and case studies
- Minimizing adverse events whilst enhancing therapeutic synergies by refining combination therapy strategies through data-informed drug pairings
- **Leveraging emerging therapeutic modalities** and their potential to reshape IBD treatment strategies to refine patient selection and optimize therapeutic outcomes

Join precision medicine, diagnostics, translational, clinical, computational biology, gastrointestinal and inflammation specialists to gain unmatched insights and form new connections, enabling you to stay at the forefront of innovation and drive meaningful progress toward truly effective care for patients with Ulcerative Colitis, Crohn's Disease and beyond.

#### Hear from Previous Attendees:

WELCOME

EXPERT SPEAKERS

AGEND/

PARTNER WITH US

▲ Intimate and the content was all very relevant. The networking sessions were great to get to know the other participants

Senior Vice President, Drug Discovery



Good talks, science, and an opportunity to learn about specifics of drug development in IBD

Director, Research Alliances



# control innate immunity

### **KEY BENEFITS OF ATTENDING**



Overcome IBD heterogeneity with digital pathology and spatial biology, enhancing patient stratification and revealing actionable molecular targets to drive therapeutic breakthroughs, with insights from Ostuka Pharma & Bristol Myers Squibb

2



Improve Efficacy with diagnostic biomarkers to refine patient subtyping to ensure the right patient gets the right drug at the right time, by Sanofi & Merck & Co.



Revolutionize clinical monitoring with advanced ultrasound technology and Al-driven imaging tools, enabling noninvasive surveillance to enhance clinical decision-making, with key learnings from Pfizer & Crohn's & Colitis Foundation



Discover novel therapeutic targets and mechanisms of action, unlocking unprecedented opportunities to deliver transformative treatments and elevate standards of care, leveraging expertise from ThirtyFiveBio & AnaptysBio

#### Unleash the potential of combination therapies to amplify treatment efficacy,

treatment efficacy, minimize adverse effects, and deliver synergistic solutions for more personalized and effective patient care, shaped by analysis from Sypyre Therapeutics & Takeda

Bowel Disease Summit May 13-15, 2025 | Boston, MA

hans

# What's New for 2025

Precision Medicine in Inflammatory Bowel Disease Summit May 13-15, 2025 | Boston, MA



25+ Expert Speakers: Learn from the foremost leaders shaping the future of

precision medicine in IBD and driving

20+ Groundbreaking Presentations:

10+ Hours of Networking: Connect

influential leaders driving innovation in

perspectives on IBD care and address critical gaps for patients with unmet

Discussions: Share your expertise,

exchange ideas, and help shape

the future of precision medicine

**1 Pre-Conference Focus Day:** Join your peers at the Technology

Innovations in IBD focus day, where

we will be bringing you the hottest

developments, from ultra-sound

technology to digital pathology

with the brightest minds and most

precision medicine for IBD

2 Transformative Panel **Discussions:** Explore fresh

2 Interactive Roundtable

needs

in IBD

3

Gain exclusive updates on clinical

trials, cutting-edge technologies, biomarker breakthroughs, and more

developments across the field

## **New Session Spotlights**



Using Ultrasound to Non-Invasively Monitor **Patient Progress for Enhanced Clinical Decision** Making

Sarah Sidhu, Global Medical Director, Gastroenterology, Pfizer

Leveraging Multi-Omics to Uncover Deeper Insights into IBD Morphology for Improved Patient Subtyping Ilan Wapinski, Head, Biomarkers & Patient Stratification, Sanofi





**Unlocking the Potential of Tulisokibart & Harnessing Biomarkers to Elevate Response Rate for Therapeutics** in IBD

Raj Kamath, Executive Director, Merck & Co.



Individual Response Trajectories in IBD Defines **Patent Clusters for Precision Medicine** 

Stefan Schreiber. Professor of Medicine. Director Department of Internal Medicine, University Hospital Schleswig-Holstein (UKSH), Kiel University





#### Advancing Combination Therapies to Change the Treatment Paradigm in IBD

Joshua Friedman, Senior Vice President, Clinical Development, Spyre Therapeutics

#### **Targeting CCR9: Advancing Precision Therapies for Inflammatory Bowel Disease** Sarah Grant, Vice President & Head, Early Clinical



Development, Respiratory & Immunology, AstraZeneca



Showcase Your Scientific Poster



We are inviting experts from biopharma to share their latest hypotheses, findings or data in a dedicated poster session. This is your chance to present your work amongst the leaders of the space, and pose questions to your peers.

Register your place to submit an abstract for review to showcase your poster\*

\*Please visit the website for the T&Cs for presenting a poster

WELCOME



# Your Expert Speakers

Precision Medicine in Inflammatory Bowel Disease Summit May 13-15, 2025 | Boston, MA

**Bryan Linggi** 

**AnaptysBio** 

Senior Director,

Translational Research



John Brian Mumm President & CEO

**Deka Biosciences Eileen Crowley** 

Assistant Professor & Pediatric Gastroenterologist, **Clinician Researcher London Health Sciences Centre** 

Scott Thacher CEO & Founder Orphagen **Pharmaceuticals** 

**Joerg Heyer** Head of Translational Science & Medicine **Palisade Bio** 

Sarah Sidhu

Vinayagam

Arunachalam

Pfizer

Global Medical Director, Gastroenterology

WELCOME

EXPERT SPEAKERS



Perspectum 🔾





4

Director & Head, Computational & Systems Biology, Early Clinical Development, GI2-TAU Takeda Stefan Schreiber

Professor of Medicine. Director Department of Internal Medicine, University Hospital Schleswig-Holstein (UKSH) Kiel University

# Technology Innovations in IBD Pre-Conference Focus Day Tuesday, May 13, 2025

8.00

Discover how AI and advanced technologies are transforming IBD therapeutic development through refined patient subtyping, optimized diagnostics, and enhanced clinical trial outcomes. This focus day delves into cutting-edge innovations, including digital pathology, spatial biology, and imaging tools, that are driving therapeutic breakthroughs and improving clinical decision-making. With expert-led sessions and unique networking opportunities, this is your chance to stay ahead of the curve in precision medicine and shape the future of IBD treatment by bringing better drugs to patients faster.

**Check-In & Light Breakfast** 

8.50 Chair's Opening Remarks Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes Harnessing Novel AI & ML Tools to Revolutionize Patient Diagnostics for 9.00 Steven Levitte **Unparalleled Personalized Therapy Opportunities** Medical Director, Product Development, · Leveraging AI-driven algorithms for standardized ME score calculation and enhancing Gastroenterology efficiency in clinical trial operations Hepatology & The potential for AI to streamline trial endpoints and address screen failures in Metabolism **IBD** studies Genentech · Exploring regulatory challenges and the need for cross-industry collaboration to **NEW COMPANY** advance AI and CDx adoption Improving Patient Subtyping with AI-Driven Insights to Unlock Better 9.30 Joerg Heyer Insights into IBD Heterogeneity & Smash the Efficacy Ceiling Head of Translational Science & Medicine · Utilizing AI to refine patient subtypes based on molecular and clinical profiles Palisade Bio · Enhancing therapeutic targeting by bridging IBD heterogeneity gaps **NEW COMPANY** · Discovering hidden subgroups to drive better therapy alignment 10.00 Morning Networking Break Harnessing AI & Data Integration to Optimize Combination Therapies & **Enhance Predictive Accuracy in IBD Care** Vinayagam Optimizing Drug Combination Strategies with AI Insights to Enhance Arunachalam 11.00 Director & Head, Efficacy & Minimize Risks in IBD Treatment Computational & Predicting optimal drug combinations for better patient outcomes Systems Biology, Early Minimizing adverse events by refining combination therapy strategies Clinical Development, Enhancing therapeutic synergies through data-informed drug pairings GI2-TAU Takeda 11.30 **Roundtable Discussion:** Revolutionizing Data Integration & Processing Pipelines to Maximize AI-Powered Predictive Accuracy in IBD Care **Roundtable Moderator:** · How can pipelines be streamlined to integrate diverse patient datasets? · Enhancing predictive accuracy by reducing noise in data processing Improving patient outcomes by leveraging advanced analytics 12.30 Lunch Break & Networking

Precision Medicine in Inflammatory Bowel Disease Summit

5



### Technology Innovations in IBD Pre-Conference Focus Day Tuesday, May 13, 2025

1.30

2.00

**Gerard Honig** 

Associate Director, Biomarker Research

**Otsuka Pharma** 

Steven Levitte Medical Director,

6

**NEW COMPANY** 

Precision Medicine in Inflammatory Bowel Disease Summit May 13-15, 2025 | Boston, MA

	Product Development, Gastroenterology Hepatology & Metabolism Genentech NEW COMPANY	2.00	<ul> <li>Digital Pathology &amp; Radiology to Optimize Patient Subtyping &amp; Outcomes</li> <li>Al to refine patient subtypes based on molecular and clinical profiles</li> <li>Enhancing therapeutic targeting by bridging IBD heterogeneity gaps</li> <li>Discovering hidden subgroups to drive better therapy alignmen</li> </ul>
		2.30	Afternoon Networking Break
	Advancing Nor	n-Invas	ive Imaging Technologies to Optimize Patient Monitoring & Treatment Strategies in IBD
	Sarah Sidhu Global Medical Director, Gastroenterology Pfizer	3.30	<ul> <li>Using Ultrasound to Non-Invasively Monitor Patient Progress for Enhanced Clinical Decision Making</li> <li>Exploring the use of ultrasound for real-time, non-invasive assessment of therapeutic efficacy in preclinical and clinical settings</li> <li>Investigating the role of advanced imaging biomarkers to inform and refine drug development strategies</li> <li>Integrating ultrasound technologies into longitudinal monitoring frameworks to improve patient stratification and treatment optimization</li> </ul>
9	John Brian Mumm President & CEO Deka Biosciences	4.00	<ul> <li>Therapeutically Restoring the IL-10 Circuit in Crohn's Patients</li> <li>People who lack sufficient IL-10 signalling develop Crohn's disease</li> <li>Inflammation is complex, driven by hyper inflammatory monocytes and pathogenic Th1/ Th17 T cells</li> <li>DK410 (VEGFR2) combines IL-10 to block monocytic inflammation and IL-4 to block Th1/Th17 polarization and enriches the cytokines in the neovasculature driven by chronic inflammation</li> </ul>

Leveraging Digital Pathology & Spatial Transcriptomics to Unlock Deeper Molecular Insights & Drive Precision Care in Crohn's & Colitis

**Revolutionize IBD Therapeutics** 

Integrating Spatial Biology & Digital Pathology to Reveal Hidden Patterns &

· Combining digital pathology and spatial transcriptomics for better stratification

Can biopharma identify actionable molecular targets through spatial mapping?

**Roundtable Discussion: Overcoming IBD Heterogeneity with AI-Driven** 

· Driving therapeutic innovations using integrated molecular insights

4.30 Chair's Closing Remarks

4.40 End of Pre-Conference Focus Day

▲ The data from the presentations were of very high standard and discussions around those presentations were spontaneous and lively ■ ■ Past Attendee, Director, Precision Medicine & Immunology, AbbVie



PARTNER WITH US

AGENDA

# Conference Day One Wednesday, May 14, 2025

**Check-In & Light Breakfast** 8.00 John Brian Mumm 8.50 **Chair's Opening Remarks** President & CEO **Deka Biosciences** Decoding IBD Heterogeneity with Better Diagnosis for Enhanced Patient Subtyping to **Improve Patient Safety & Response Rate in Clinical Trials** 9.00 Leveraging Multi-Omics to Uncover Deeper Insights into IBD Heterogeneity for Improved Patient Subtyping Ilan Wapinski Head, Biomarkers & · How to integrate transcriptomics across diverse cohorts for granular patient subtyping Patient Stratification · Identifying novel markers linked to inflammation signatures to enhance clinical Sanofi trial outcomes **NEW COMPANY** · How to bridge gaps between phenotypic data and actionable therapeutic strategies in IBD Unlocking the Potential of Tulisokibart & Harnessing Biomarkers to Elevate 9.30 **Response Rate for Therapeutics in IBD**  Sharing insights from the integration of a diagnostic tool in a phase II trial, highlighting Raj Kamath successes, challenges, and learnings from its development **Executive Director**  Discussing the role of patient stratification in advancing therapeutic precision and Merck & Co. optimizing treatment pathways for IBD · Exploring the future potential of diagnostic innovations in clinical trials and their role in shaping precision medicine strategies 10.00 Morning Speed Networking Break As the Precision Medicine and IBD community come together, this valuable session offers the perfect opportunity to connect with peers and build meaningful relationships. Attendees will have the chance to meet, network, and collaborate with industry leaders driving innovation in IBD care. Harnessing Prognostic Biomarkers & Monitoring Tools to Enable Personalized Treatment Plans & Revolutionize Therapeutic Efficacy **Stefan Schreiber** Professor of Medicine, Individual Response Trajectories in IBD Defines Patent Clusters for 11.00 Director Department **Precision Medicine** of Internal Medicine, University Hospital Large level of individual heterogeneity in patients with IBD including therapy responses Schleswig-Holstein · Response dynamics cluster patients into new subpopulations (UKSH) · Difference in clinical therapy response are underlaid by biomarker profiles **Kiel University NEW COMPANY** 11.30 Advancing IBD Precision Therapy Through Multimodal Real-World Data & Agentic Al **Jason Maron**  Leveraging expansive patient volumes and deep longitudinal data to identify actionable Senior Director, patterns in IBD Partnerships Harnessing Multimodal AI to integrate clinical, imaging, and molecular data for Nference actionable IBD insights Highlighting real-world case studies that illustrate the clinical and research impact of AI-powered analyses **Roundtable Moderator: Roundtable Discussion: Advancing Disease Prediction through the** Stefan Schreiber 12.00 Professor of Medicine, **Development & Validation of Prognostic Biomarkers for Personalized Director Department IBD** Treatments of Internal Medicine, What is the clinical utility of biomarkers in predicting disease course? University Hospital Can biopharma identify immune profiles linked to patient outcomes in early IBD stages? Schleswig-Holstein How can we accelerate the validation of biomarkers to enhance treatment efficacy? (UKSH) **Kiel University** 12.30 Lunch Break & Networking

Precision Medicine in Inflammatory

May 13-15, 2025 | Boston, MA

**Bowel Disease Summit** 

+1 617 455 4188 info@hansonwade.com
 www.precision-medicine-in-ibd.com Companion Diagnostics



# **Conference Day One** Wednesday, May 14, 2025

1.30

**IBD** patients

**Ben Kostiuk** 

Partnerships

Foundation

Director, Life Science

Crohn's & Colitis

NEW COMPANY



		strategies in the pursuit of precision medicine
	2.00	Digital Pathology & Endoscopy in IBD Central Reads: Streamlining Clinical Trials
Reema Kainth Product Specialist, Digital Pathology & Endoscopy Perspectum		<ul> <li>Centralized Reads: Centralized review of medical images and videos by expert readers in IBD clinical trials</li> <li>Quality Control and Consistency: High-quality results by applying standardized protocols and advanced image analysis tools</li> <li>Optimized Workflow: Integrating a customizable workflow to optimize clinical trial design and maximise outcomes</li> </ul>
	2.10	A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells
Scott Thacher CEO & Founder Orphagen Pharmaceuticals		<ul> <li>Antagonists to retinoic acid receptor-alpha (RARα) block upregulation of α4α7 and CCR9 during T cell activation in mesenteric lymph nodes</li> <li>Daily oral dosing of an RARα antagonist inhibits intestinal epithelial damage in a mouse model of colitis. In separate models, inflammatory T cell migration to the intestinal lining is also suppressed</li> <li>Preclinical safety findings for the highly selective RARα antagonist OR-812 support further development</li> </ul>
	2.40	<b>Poster Session &amp; Networking</b> Join the Precision Medicine and IBD community in this interactive session, showcasing pioneering research and innovative approaches in IBD care. Attendees will have the chance to share their work, engage with their peers, and discuss advancements shaping the future of precision medicine for IBD.
		D Treatment with Optimized Combination Therapies & ion Modalities to Offer More Efficacious Therapeutics
Denel Discussion		
		orizons in Precision Medicine: Exploring New Modalities &
<ul> <li>Technologies for I</li> <li>Discussing emergin</li> <li>Identifying critical cl</li> <li>Envisioning the intervision</li> </ul>	<b>BD</b> ng therapeu hallenges a egration of n	tic modalities and their potential to reshape IBD treatment strategies and opportunities in developing precision medicine approaches novel technologies to improve patient outcomes and drive innovation
Technologies for I         • Discussing emergin         • Identifying critical cl         • Envisioning the inte         • How will combination         • How will combination         • Laurence Cheng         Executive Director & F         Medicine Therapeutic         Head, Inflammation and         Disease	BD ng therapeu hallenges a egration of n on therapies Precision Area	tic modalities and their potential to reshape IBD treatment strategies and opportunities in developing precision medicine approaches
Technologies for I         • Discussing emergin         • Identifying critical cl         • Envisioning the inte         • How will combination         Laurence Cheng         Executive Director & F         Medicine Therapeutic         Head, Inflammation and	BD ng therapeu hallenges a egration of n on therapies Precision Area	<ul> <li>And opportunities and their potential to reshape IBD treatment strategies and opportunities in developing precision medicine approaches novel technologies to improve patient outcomes and drive innovation is shape the future of treatments for IBD?</li> <li>Neil Humphryes-Kirilov Associate Director, Human Genomics C4X Discovery</li> <li>Neil Science Partnerships Crohn's &amp; Colitis</li> </ul>
Technologies for I         • Discussing emergin         • Identifying critical cl         • Envisioning the inte         • How will combination         • How will combination         • Laurence Cheng         Executive Director & F         Medicine Therapeutic         Head, Inflammation and Disease	BD ng therapeu hallenges a egration of n on therapies Precision Area nd Rare 4.30	tic modalities and their potential to reshape IBD treatment strategies and opportunities in developing precision medicine approaches hovel technologies to improve patient outcomes and drive innovation a shape the future of treatments for IBD? Neil Humphryes-Kirilov Associate Director, Human Genomics C4X Discovery Medicine approaches Ben Kostiuk Director, Life Science Partnerships Crohn's & Colitis Foundation
Technologies for I         • Discussing emergin         • Identifying critical cl         • Envisioning the inte         • How will combination         • How will combination         • Laurence Cheng         Executive Director & F         Medicine Therapeutic         Head, Inflammation and         Disease         Amgen         Senior Vice President,         Clinical Development         Spyre Therapeutics	BD ng therapeu hallenges a egration of n on therapies Precision Area nd Rare 4.30	<ul> <li>Addressing the natural questions around patient selection for combination therapies</li> </ul>
Technologies for I         • Discussing emergin         • Identifying critical cl         • Envisioning the inte         • How will combination         • How will combination         • Laurence Cheng         Executive Director & F         Medicine Therapeutic         Head, Inflammation at         Disease         Amgen         Senior Vice President,         Clinical Development         Spyre Therapeutics         NEW COMPANY         Month Brian Mumm         President & CEO	BD ng therapeu hallenges a gration of n on therapies Precision Area nd Rare 4.30	<ul> <li>A structure of treatment is trategies in developing precision medicine approaches novel technologies to improve patient outcomes and drive innovation is shape the future of treatments for IBD?</li> <li>Neil Humphryes-Kirilov Associate Director, Human Genomics C4X Discovery</li> <li>Neil Science Partnerships Crohn's &amp; Colitis Foundation</li> <li>Advancing Combination Therapies to Change the Treatment Paradigm in IBD therapy</li> <li>Scientific and clinical rationale for targeting o4β7, TL1A, and IL-23 pathways in IBD therapy</li> <li>Nonclinical data demonstrating enhanced efficacy and extended half-life of biologics for combination treatments</li> </ul>

**Bridging Innovation & Implementation: Driving Precision Medicine Forward in IBD Through Data, Technology & Translational Science** 

Precision Medicine Meets the Real World: Lessons from IBD Plexus

system as well as other landmarks in their disease journey

SPARC IBD is a real world study that follows the natural history of disease for over 6000


In this presentation, we show the touch points that patients have with the health care

These interactions are opportunities to learn more about patients or apply treatment





# Conference Day Two Thursday, May 15, 2025



9

hansonwade

Precision Medicine in Inflammatory Bowel Disease Summit

May 13-15, 2025 | Boston, MA

REGISTER YOUR PLACE

# Conference Day Two Thursday, May 15, 2025

12.30 Lunch Break & Networking

TD

10



Deciphering Nove	I Target	as & Preclinical Models to Accelerate Precision IBD Therapies & Enhance Clinical Success
Josselin Caradec Head, Biology ThirtyFiveBio NEW COMPANY	1.30	<ul> <li>Deciphering GPR35: A Novel Target for Epithelial-Driven Therapeutics in IBD</li> <li>Unravelling the role of GPR35 in epithelial biology to address inflammatory bowel disease progression</li> <li>Investigating the therapeutic potential of GPR35 antagonists in preclinical models and patient-derived systems</li> <li>Exploring the use of biomarkers to stratify patients for targeted therapeutic interventions and enhanced clinical outcomes</li> </ul>
Roundtable Moderator: Paul Kayne Vice President, Biological Sciences Palatin Technologies	2.00	<ul> <li>Roundtable Discussion: Advancing Autoimmune Therapeutics: Precision Approaches to Inflammation</li> <li>Which emerging targets do you see as most promising for transforming the treatment of autoimmune and inflammatory diseases</li> <li>What are the key hurdles to validating novel targets, clinically?</li> <li>Where do you see the most opportunity to combine precision medicine tools (e.g. multi-omics, digital pathology, AI) with new target exploration to drive better outcomes in autoimmune disease?</li> </ul>
Paul Kayne Vice President, Biological Sciences Palatin Technologies	2.30	<ul> <li>Inflammatory Resolution of Ulcerative Colitis – The Melanocortin System</li> <li>Melanocortin agonists don't block they immune system, they promote resolution of inflammation</li> <li>Animal studies demonstrate the effectiveness and mechanisms of action of these agonists</li> <li>A Phase 2 clinical study showed 33% remission vs 0% placebo and 78% clinical response vs 33% placebo</li> </ul>
Paul Kayne Vice President, Biological Sciences Palatin Technologies	3.00	Chair's Closing Remarks
	3.05	End of 3 <sup>rd</sup> Precision Medicine in Inflammatory Bowel Disease Summit

It was an intimate meeting with excellent representation from big pharma and biotech in the IBD space. I was able to have meaningful conversations with most attendees whether through round table discussions or social breaks

Past Speaker, Associate Director of Immunology, Takeda



# **Partner With Us**



# EXPERT SPEAKERS

### **Expertise Partner**

Powering quantum leaps in human health. nference partners with health systems to transform decades of rich and predominantly unstructured data captured in electronic medical records (EMR) into powerful software solutions that enable scientists to discover and develop the next-generation of personalized diagnostics and treatments for patients worldwide.

www.nference.com

#### **Innovation Partner**

Perspectum is a global medical imaging company delivering innovative solutions for clinical trials. Taking a holistic approach to inflammatory bowel diseases, the company leverages advanced digital pathology and endoscopy solutions. Our end-to-end solution covers the entire reading workflow—from site to final report—delivering faster, more accurate endpoint assessments. Our platform is customizable to your specific protocol requirements, eliminating workflow inefficiencies while reducing sponsor burden. Perspectum has supported over 75+ trials, demonstrating proven scalability for large-scale clinical studies.

www.perspectum.com/for-professionals/pharma-solutions



nference®

Perspectum 😔

#### **Event Partner**

Alimentiv is a leading gastroenterology CRO providing tailored clinical trial management, central imaging, precision medicine, and statistical services. Over the past 20 years, Alimentiv has become recognized for providing unmatched end-to-end support for complex IBD trials. As a pioneer in IBD research, Alimentiv leverages cutting-edge multi-omics tissue analytics by offering custom immunostaining, digital image analysis, spatial biology, and bioinformatics services to enable actionable, data-driven insights.

www.alimentiv.com

# **GET INVOLVED**



Eirini Karavasili Business Development Manager C +1 617 455 4188 Sponsor@hansonwade.com





# **Partner With Us**



EXPERT SPEAKERS

### Forge Strong Connections with Global Leaders in Precision Medicine for IBD

The **3**<sup>rd</sup> **Precision Medicine in Inflammatory Bowel Disease Summit** is your premier opportunity to connect with senior decision-makers in immunology, gastroenterology, and precision medicine who are committed to driving innovation and solving challenges in this evolving field.

Join an audience of 80+ senior key opinion leaders actively seeking partnerships in data management, AI/ML, technological innovation, multi-omics sequencing and analysis, biomarker development, and other transformative services. They are eager to connect and collaborate with fellow leaders driving advancements in these fields.



Showcase Your Innovative Technologies & Diagnostic Services to a Targeted Audience of Senior Leaders in Precision Medicine for IBD

Showcase your cutting-edge technologies and diagnostic services to an audience of senior leaders driving unprecedented innovation in precision medicine for IBD. With agenda topics ranging from Al-driven patient stratification to multi-omics analysis, combination therapies, and advanced imaging tools, align your solutions with the most pressing challenges in IBD care. Leverage strategic exposure before, during, and after the summit to demonstrate your impact, foster meaningful partnerships, and solidify your position as a leader transforming outcomes for patients with inflammatory bowel disease.



Gain Strategic Market Insights to Stay Ahead in the Dynamic IBD Landscape

Understand the key priorities of biopharma and precision medicine leaders as they seek innovative tools to improve patient stratification, disease monitoring, and therapeutic outcomes. Position your solutions to meet the latest regulatory requirements and scientific advancements, ensuring you remain a critical partner in advancing care for patients with IBD.



SENIORITY OF ATTENDEES\*

Forge High-Impact Collaborations with Influential Stakeholders from Biopharma, Diagnostics, & Academic Institutions

Participate in dedicated networking opportunities, including speed networking and targeted discussions, to build valuable partnerships that drive progress in IBD diagnostics and patient care. Collaborate with leaders sharing a common goal of advancing precision medicine and improving outcomes for patients with inflammatory bowel disease.

C-Level: 15%

**President**/


Director/Head: 30%

Vice President: 16%

Manager/Scientist: 21%

Professor/Other: 18%

### **TYPES OF COMPANIES ATTENDING\***



#### \*Statistics Taken from the 2nd Precision Medicine in Inflammatory Bowel Disease Summit

# **GET INVOLVED**



Eirini Karavasili Business Development Manager C +1 617 455 4188 Sponsor@hansonwade.com





# **Ready to Register?**

### **3 Easy Ways to Book**

ĸ

 $\times$ 

www.precision-medicine-in-ibd.com/ take-part/register

- Tel: +1 617 455 4188
- Email: info@hansonwade.com



**DISCOVER** how leading companies are leveraging groundbreaking technologies and multi-omics approaches to address the complexity of inflammatory bowel disease and advance next-generation precision therapeutics



**BUILD** your understanding of the challenges, strategies, and solutions to improve patient stratification, biomarker development, and therapeutic efficacy in IBD

**CONNECT** with your peers and community from leading pharma, biotech, and academic institutions to forge lasting connections, foster meaningful collaborations, and identify the best solutions for advancing precision medicine in IBD

Drug Developer Pricing*	Standard Pricing	On The Door
Conference + Focus Day	\$4,097 <b>(Save \$100)</b>	\$4,197
Conference Only	\$2,899 <b>(Save \$100)</b>	\$2,999
Academic & Not-for-Profit Pricing**	Standard Pricing	On The Door
Conference + Focus Day	\$3,497 <b>(Save \$100)</b>	\$3,597
Conference Only	\$2,499 <b>(Save \$100)</b>	\$2,599
Service & Solution Provider Pricing	Standard Pricing	On The Door
Conference + Focus Day	\$4,997 <b>(Save \$100)</b>	\$5,097
Conference Only	\$3,599 <b>(Save \$100)</b>	\$3,699

\*To qualify for the drug developer rate your company must have a public drug pipeline, and not provide pay-for services to any other company. Please visit the website for full pricing options or email info@hansonwade.com

\*\*To qualify for the academic and research rate you must be full time academic or employee of a not-for-profit organization. Please visit the website for full pricing options or email info@hansonwade.com

### **Team Discounts\*\*\***

- 10% discount 2 Attendees
- 15% discount 3 Attendees •
- 20% discount 4+ Attendees

\*\*\*Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com

### Venue

**Revere Hotel Boston Common** 200 Stuart Street, Boston, MA 02116, United States

www.reverehotel.com

#### **TERMS & CONDITIONS**

13

Full payment is due on registration. Cancellation and Substitution Policy Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary authere to the event programme as auvertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third you involution contraction of the second state WELCOME

EXPERT SPEAKERS

AGEND/



